Healthcare
Ion Beam Applications S.A.(IOBCF)
Live Price
Offline$19.30
+0.00% today
1Y Change
+37.96%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $390.00M
- Revenue Growth
- +24.5%
- EPS Growth
- +34.4%
- Dividend Yield
- 1.8%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ion Beam Applications S.A. (IOBCF) is a Healthcare stock with a market cap of $390.00M and listed on OTC. The stock last traded around $19.30 and up 38.0% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +24.5%, EPS growth of +34.4%, a dividend yield of 1.8%. What stands out right now is revenue +24.5%, EPS +34.4%, free cash flow -94.3% with operating margin 4.4% and ROIC 7.2%. The dividend is present but secondary, with a yield around 1.8%. Valuation already assumes a fairly strong business story at P/E 31.2 and price/sales 0.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IOBCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+24.5% vs +7.6% peer median
Operating Margin
Below sector median
+4.4% vs +19.4% peer median
P/E
Below sector median
31.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 27, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +24.5% and EPS at +34.4%, with operating margin around 4.4%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 27, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 27, 2026 | โ | +0.0% | +0.0% | +6.7% |
2025 Aug 27, 2025 | โ | +4.8% | +5.3% | +2.6% |
2025 May 22, 2025 | +13.2% | -0.4% | -0.4% | +3.7% |
Benchmark Edge
IOBCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IOBCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IOBCF Max Drawdown
-20.43%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IOBCF and SPY.
Company Overview
Ion Beam Applications S.A.
Other OTC
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
- Leadership
- Olivier Legrain
- IPO Date
- Sep 24, 2001
- Employees
- 2.1k
- Street Address
- 3, Chemin du Cyclotron
- Mailing
- Louvain-la-Neuve, 1348
- Region
- Louvain-la-Neuve, BE
- Reporting Currency
- USD
- Investor Line
- 32 1 047 58 11
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 31.2
- EV/EBITDA
- 11.9
- Price/Sales
- 0.6
- Price/Book
- 3.1
Growth
- Revenue
- +24.5%
- EPS
- +34.4%
- Free Cash Flow
- -94.3%
Profitability
- Gross Margin
- 32.2%
- Operating Margin
- 4.4%
- Net Margin
- 2.0%
- ROE
- 10.3%
- ROIC
- 7.2%
Balance Sheet
- Debt/Equity
- 0.92
- Current Ratio
- 0.99
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.